This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Spectral MD Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Spectral MD Holdings.

Wichtige Informationen

79.2%

Wachstumsrate der Gewinne

79.2%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum22.2%
Wachstumsrate der Einnahmen51.0%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert06 Sep 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

AIM:SMD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20251193431N/A2
12/31/202438-3-10-92
12/31/202326-10-6-62
3/31/202325-6-4-4N/A
12/31/202225-3-1-1N/A
9/30/202223-3-1-1N/A
6/30/202220-4-2-2N/A
3/31/202218-5-3-3N/A
12/31/202115-5-3-3N/A
9/30/202116-400N/A
6/30/202117-322N/A
3/31/202117-133N/A
12/31/202017144N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SMD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).

Ertrag vs. Markt: SMD is forecast to become profitable over the next 3 years, which is considered above average market growth.

Hohe Wachstumserträge: SMD is expected to become profitable in the next 3 years.

Einnahmen vs. Markt: SMD's revenue (51% per year) is forecast to grow faster than the UK market (4.1% per year).

Hohe Wachstumseinnahmen: SMD's revenue (51% per year) is forecast to grow faster than 20% per year.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if SMD's Return on Equity is forecast to be high in 3 years time


Wachstumsunternehmen entdecken